Invesco Pharmaceuticals ETF
PJP
92 hedge funds and large institutions have $87.7M invested in Invesco Pharmaceuticals ETF in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 32 reducing their positions, and 14 closing their positions.
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2% more funds holding
Funds holding: 90 → 92 (+2)
2.05% less ownership
Funds ownership: 15.64% → 13.59% (-2%)
22% less capital invested
Capital invested by funds: $113M → $87.7M (-$25.3M)
47% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 32
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.54M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$957K |
| 3 |
FSA
Financial Sense Advisors
San Diego,
California
|
+$796K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$563K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$376K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$13.3M |
| 2 |
LPL Financial
San Diego,
California
|
-$2.51M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.32M |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$1.38M |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$1.38M |
PJP Hedge Fund Activity: Q4 2017 in Review
92 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q4 2017, worth a combined $87.7M — down 22% from $113M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PJP positions and 14 closed out — a net gain of 2 holders — while 17 added to existing stakes and 32 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.54M. The largest seller was Two Sigma Securities, cutting an estimated $13.3M.
- 92 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q4 2017, up from 90 in Q3 2017.
- Funds reported $87.7M of Invesco Pharmaceuticals ETF stock for Q4 2017, down 22% quarter-over-quarter.
- 16 funds opened new Invesco Pharmaceuticals ETF positions in Q4 2017 and 14 closed out, a net change of +2 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q4 2017 was Tower Research Capital (TRC), an estimated $1.54M added.
- The largest Invesco Pharmaceuticals ETF seller in Q4 2017 was Two Sigma Securities, an estimated $13.3M sold.
Based on aggregated 13F filings for Q4 2017.